“Women deserve full information, not corporate silence.”
The promise
Following review of neurodevelopmental risk studies, Kennedy ordered FDA to update pregnancy-warning labels on acetaminophen products. The decision aimed at transparency without restricting access. Pharma groups opposed the change, claiming weak evidence; advocacy groups welcomed acknowledgment of risk. Updated labeling entered Federal Register publication in May 2025.





